Asia Pacific Bioreactors Market
The Asia Pacific bioreactors market was valued at US$ 706.74 million in 2022 and is expected to reach US$ 1,488.10 million by 2030; it is estimated to grow at a CAGR of 9.8% from 2022 to 2030.
Advancement in the field of bioreactors has opened many opportunities for the market players. Leading players have come up with innovative products in the last few years. The improvement in the bioreactors offers a faster and easier production of biopharmaceuticals at reduced production costs. Also, the investments from public and private investors are rising for the bioreactors. The rise in the venture is enabling technological developments and standard biological parts. In February 2021, WuXi Biologics' MFG5 Drug Substance (DS) manufacturing facility in China launched a GMP operation with a capacity of 36,000L and deployed nine 4,000L single-use bioreactors. As a major milestone in the company's global capacity planning, the GMP implementation of MFG5 increases WuXi Biologics' current capacity to 90,000L, significantly expanding its ability to support global partners.
The new bioreactors are developed for the growth of adherent cells on microcarriers that enable rapid, scalable cell culture processes in the development of vaccines. The launch of such new bioreactors enhanced the portfolio of the company in the bioreactors market.
Advancement in bioreactors has added various solutions for most industries, such as pharmaceutical, petrochemical, food, and agriculture. Therefore, technological advancements are expected to boost innovations in the bioreactors market in the coming years.
In China, bioreactors have experienced tremendous growth owing to an increasing number of bioreactors projects and partnerships in the country. Developments such as partnerships and increasing focus on research and development activities by pharmaceutical and biotechnology companies have accelerated the growth of the market in China. For instance, in January 2022, Shanghai ZhenGe Biotech Co., Ltd., a contract development and manufacturing organization (CDMO) service provider, completed a successful round C financing, raising a total of US$ 100 million. The funding round was led by Goldman Sachs Asset Management and Sofina, with additional investments from Novo Holdings A/S, Qiming Venture Capital, IDG Capital, LYFE Capital, Junxin Capital, and Cowin Capital. Proceeds from round C strengthened R&D and helped build 15,000L production lines to meet growing demand from existing and new customers with cost-effective and high-quality solutions.
Developments by the companies in China are also boosting the bioreactors market growth. For instance, in October 2023, WuXi Biologics launched a new bioprocessing platform, WuXiUITM, for cost-effective commercial manufacturing and desirable product quality. WuXiUITM intensifies fed-batch solutions, enhancing the productivity and quality of various mammalian cells and product modalities.
The demand for bioreactors is growing further owing to their application in cultured meat production. Over the last several decades, China has made sustained and large R&D investments in biotechnology. One of China's strategic aims is to use biotechnology to help accomplish national food security goals. Amidst the rise of alternative proteins, China is now turning its attention to the innovative cultivated meat industry.
Strategic insights for the Asia Pacific Bioreactors provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 706.74 Million |
| Market Size by 2030 | US$ 1,488.10 Million |
| Global CAGR (2022 - 2030) | 9.8% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2030 |
| Segments Covered |
By Scale
|
| Regions and Countries Covered | Asia-Pacific
|
| Market leaders and key company profiles |
The geographic scope of the Asia Pacific Bioreactors refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.
The Asia Pacific bioreactors market is segmented based on scale, application, technology, end user, and country. Based on scale, the Asia Pacific bioreactors market is segmented into lab-scale production, pilot-scale production, and full-scale production. The pilot-scale production segment held the largest market share in 2022.
In terms of application, the Asia Pacific bioreactors market is categorized into microbial application, cell culture application, and others. The cell culture application segment held the largest market share in 2022.
By technology, the Asia Pacific bioreactors market is bifurcated into fed-batch bioreactors and perfusion bioreactors. The fed-batch bioreactors segment held a larger market share in 2022.
Based on end user, the Asia Pacific bioreactors market is categorized into biopharma manufacturers, research and development organizations, and contract manufacturing organization. The research and development organizations segment held the largest market share in 2022.
Based on country, the Asia Pacific bioreactors market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific bioreactors market share in 2022.
Applikon Biotechnology BV, bbi-biotech GmbH, General Electric Co, Merck KGaA, Pall Corp, PBS Biotech Inc, Sartorius AG, Solaris Biotechnology SRL, and Thermo Fisher Scientific Inc are some of the leading players operating in the Asia Pacific bioreactors market.
The Asia Pacific Bioreactors Market is valued at US$ 706.74 Million in 2022, it is projected to reach US$ 1,488.10 Million by 2030.
As per our report Asia Pacific Bioreactors Market, the market size is valued at US$ 706.74 Million in 2022, projecting it to reach US$ 1,488.10 Million by 2030. This translates to a CAGR of approximately 9.8% during the forecast period.
The Asia Pacific Bioreactors Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Bioreactors Market report:
The Asia Pacific Bioreactors Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Bioreactors Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Bioreactors Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Asia Pacific Bioreactors Market
